Alkermes, Inc.: all 92 studies

Page 1 of 1. Open to participants first (8), then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)RecruitingNCT07755410Phase 2
• An Expanded Access Program (EAP) for OLZ/SAM in Pediatric Participants With Schizophrenia or Bipolar I Disorder (ALKS 3831-315)AvailableNCT07744113
• A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)RecruitingNCT07540897Phase 3
• A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2RecruitingNCT07502443Phase 3
• A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1RecruitingNCT07455383Phase 3
• A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic HypersomniaRecruitingNCT06767683Phase 2/3
• Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I DisorderRecruitingNCT05303064Phase 3
• Long-term Safety Extension Study of OLZ/SAM in Pediatric SubjectsEnrolling by invitationNCT04987229Phase 3
• Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)TerminatedNCT05092360Phase 3Results posted
• A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck CancerCompletedNCT04144517Phase 2Results posted
• A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD)TerminatedNCT03610048Phase 3Results posted
• A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of SchizophreniaCompletedNCT03345979Phase 3Results posted
• Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831CompletedNCT03201757Phase 3Results posted
• A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)CompletedNCT03188185Phase 3Results posted
• Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I DisorderCompletedNCT03187769Phase 3Results posted
• A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With SchizophreniaCompletedNCT02873208Phase 3Results posted
• A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid TumorsCompletedNCT02799095Phase 1/2Results posted
• Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in NarcolepsyCompletedNCT02720744Phase 3Results posted
• Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROLCompletedNCT02696434Phase 3Results posted
• A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)CompletedNCT02694328Phase 3Results posted
• A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With SchizophreniaCompletedNCT02669758Phase 3Results posted
• A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)CompletedNCT02634346Phase 3Results posted
• A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With SchizophreniaCompletedNCT02634320Phase 4Results posted
• Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension)CompletedNCT02537574Phase 3Results posted
• A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 StudyCompletedNCT02218008Phase 3Results posted
• A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use DisorderCompletedNCT02161718Phase 2Results posted
• A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 StudyCompletedNCT02158546Phase 3Results posted
• A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 StudyCompletedNCT02158533Phase 3Results posted
• A Long-Term Safety Study of ALKS 5461CompletedNCT02141399Phase 3Results posted
• A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)CompletedNCT02085135Phase 3Results posted
• A Study of ALKS 3831 in Adults With SchizophreniaCompletedNCT01903837Phase 2Results posted
• An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)CompletedNCT01895452Phase 3Results posted
• A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)CompletedNCT01626456Phase 3Results posted
• A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)CompletedNCT01500200Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With SchizophreniaCompletedNCT01469039Phase 3Results posted
• A Study of VIVITROL in the Prevention of Re-arrest and Re-incarcerationCompletedNCT01453374Phase 4Results posted
• ALK21-006: Long-Term Study of Medisorb® Naltrexone (VIVITROL®)CompletedNCT01218997Phase 3Results posted
• ALK21-004: Single-dose Opiate Challenge of Medisorb® Naltrexone (VIVITROL®) in Adults Who Use OpioidsCompletedNCT01218984Phase 2Results posted
• ALK21-003EXT: An Extension of Study ALK21-003 (NCT01218958) to Test the Long-term Safety of Medisorb® Naltrexone (VIVITROL®)CompletedNCT01218971Phase 3Results posted
• ALK21-003: Study of Medisorb® Naltrexone (VIVITROL®) in Alcohol-Dependent AdultsCompletedNCT01218958Phase 3Results posted
• ALK21-021: A Safety Study of Medisorb® Naltrexone (VIVITROL®) Administered to Health Care ProfessionalsCompletedNCT00834080Phase 3Results posted
• ALK27-001: A Study of Trospium Inhalation Powder (TrIP)Administered to Subjects With COPDCompletedNCT00801684Phase 2Results posted
• ALK21-013: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) in Adults With Opioid DependenceCompletedNCT00678418Phase 3Results posted
• ALK21-018: Effects of Medisorb® Naltrexone (VIVITROL®) on Alcohol Craving in Treatment-seeking, Alcohol-dependent AdultsCompletedNCT00511836Phase 4Results posted
• ALK21-014: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) After Enforced AbstinenceCompletedNCT00501631Phase 3Results posted
• ALK21-006EXT: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol- or Opioid-dependent Adults (Extension of Study ALK21-006 [NCT01218997])TerminatedNCT00156936Phase 3Results posted
• ALK21-010: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol-dependent AdultsCompletedNCT00156923Phase 3Results posted
• A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic HypersomniaActive, not recruitingNCT06843590Phase 2
• Observational Study of LUMRYZ in NarcolepsyCompletedNCT06792708
• A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2CompletedNCT06555783Phase 2
• Safety and Efficacy of FT218 in Idiopathic Hypersomnia (REVITALYZ)CompletedNCT06525077Phase 3
• A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)CompletedNCT06358950Phase 2
• Study of the Breast Milk Pharmacokinetics of Olanzapine and SamidorphanCompletedNCT05547100Phase 1
• Phase 1 ALKS 1140 in Healthy AdultsTerminatedNCT05019105Phase 1
• Phase 1 Study of OLZ/SAM in Pediatric Subjects With Bipolar I DisorderCompletedNCT04987658Phase 1
• Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6TerminatedNCT04830124Phase 2
• Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)Active, not recruitingNCT04592653Phase 1/2
• An Open Label Study of FT218 in Subjects With NarcolepsyCompletedNCT04451668Phase 3
• A 28 Day Parallel Group Study to Assess the Effects of RDN-929TerminatedNCT03963973Phase 1
• Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS)CompletedNCT03919994
• A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)CompletedNCT03861793Phase 1/2
• Single and Multiple Ascending Dose and Food Effect PK Study in Healthy Adult and Elderly SubjectsCompletedNCT03668314Phase 1
• A Non-therapeutic Feasibility Study of the Radioligand [11C]-UCB-J for Imaging Synaptic DensityCompletedNCT03577262Early Phase 1
• An Insulin Sensitivity Study in Healthy SubjectsCompletedNCT02922426Phase 1
• A Phase 1 Safety Study in Adults With SchizophreniaCompletedNCT02804568Phase 1
• A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective DisorderCompletedNCT02636842Phase 1
• A Drug-drug Interaction Study of ALKS 5461 in Healthy VolunteersCompletedNCT02545439Phase 1
• A Water Consumption Study of ALKS 5461 in Healthy VolunteersCompletedNCT02521857Phase 1
• Pharmacokinetics and Safety of ALKS 5461 in Subjects With Renal Impairment and Normal Renal FunctionCompletedNCT02508506Phase 1
• A Study of [14c]-Samidorphan (Also Known as ALKS 33) in Healthy, Male VolunteersCompletedNCT02504463Phase 1
• A Study to Evaluate the Effect of ALKS 5461 on QT Intervals in Healthy VolunteersCompletedNCT02479308Phase 1
• Pharmacokinetics and Safety of ALKS 5461 in Healthy Subjects and Subjects With Hepatic Impairment and Normal Hepatic FunctionCompletedNCT02452801Phase 1
• A Study of the Abuse Liability Potential of ALKS 5461 in Healthy, Non-Dependent, Recreational Opioid UsersCompletedNCT02413281Phase 1
• An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable SchizophreniaCompletedNCT02320032Phase 1
• A Drug-Drug Interaction Study of ALKS 5461 in Healthy VolunteersCompletedNCT02272764Phase 1
• A Study of the Abuse Liability Potential of Samidorphan in Healthy, Non-Dependent, Recreational Opioid UsersCompletedNCT02218021Phase 1
• A Study of ALKS 5461 in Healthy VolunteersCompletedNCT02068105Phase 1
• A Study of ALKS 9072 in Subjects With Chronic Stable SchizophreniaCompletedNCT01493726Phase 1
• Efficacy, Safety and Tolerability Study of N1539 in Subjects After Abdominal Laparoscopic SurgeryTerminatedNCT01436032Phase 3
• ALK21-025: Vivitrol's Cost and Treatment Outcomes RegistryCompletedNCT01422837
• ALK37-007: Evaluation of Safety and Efficacy of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)CompletedNCT01418092Phase 2
• ALK37-005: A Study of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)CompletedNCT01382797Phase 2
• ALK33BUP-201: Safety and Tolerability Study of ALKS 33-BUP (ALKS 5461) Administration in Subjects With MDDCompletedNCT01381107Phase 1/2
• ALK33BUP-101: Safety and Pharmacodynamic Effects of ALKS 33-BUP Administered Alone and When Co-administered With CocaineCompletedNCT01366001Phase 1
• ALK37-003: A Study of RDC-1036 (ALKS 37) in Adults With Opioid-induced Constipation (OIC)CompletedNCT01100151Phase 2
• ALK33-101: A Study of RDC-0313 (ALKS 33) in Adults With Binge Eating DisorderCompletedNCT01098435Phase 2
• Study to Evaluate the Efficacy, Safety and Tolerability of N1539CompletedNCT01084161Phase 2
• ALK33-005: A Study of ALKS33 (RDC-0313) in Adults With Alcohol DependenceCompletedNCT00981617Phase 2
• Single Dose Study of N1539 in the Treatment of Pain Secondary to Dental Impaction SurgeryCompletedNCT00945763Phase 2
• ALK29-002: A Study of Baclofen Formulations in Healthy AdultsCompletedNCT00802035Phase 1
• ALK33-001: A Study of RDC-0313 Administered to Healthy AdultsCompletedNCT00800319Phase 1
• The Safety and Effectiveness of RMP-7 Plus Amphotericin B in Patients With HIV and Cryptococcal MeningitisCompletedNCT00002316Phase 1

← Alkermes, Inc. overview and focus areas